A Phase 2 interventional study of Paracetamol and Artesunate-amodiaquine in COVID-19, sponsored by Shin Poong Pharmaceutical Co. Ltd.. Completed at 1 site in South Africa. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-07-28.
Sponsored by Shin Poong Pharmaceutical Co. Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in COVID-19 with a site in South Africa — 7 open to participants now, 9 under way, 5 of them phase 3. COVID-19 · South Africa.
Among the 109 studies in COVID-19 with a site in South Africa, this one is the 61st largest by enrollment of the 95 interventional ones that give a count, is one of 38 that started in 2020, is one of 21 in phase 2, and was the 24th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →7 of the 109 studies in COVID-19 with a site in South Africa are open now. Recruiting first, the newest first:
Douglas D. Fraser · Sites in South Africa, United States, Brazil and 4 more countries
Ages 18–65
Pfizer · Sites in South Africa, United States, Argentina and 16 more countries
Ages 12+
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in South Africa
Ages 18+
AstraZeneca · Sites in South Africa, United States, Argentina and 36 more countries
Ages 18+
Pfizer · Sites in South Africa, United States, Bulgaria and 4 more countries
Ages 0–17
A study can be open while its sites in South Africa have not opened yet or have stopped. Only those recruiting at a site in South Africa →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 50 · Phase 3 55
First in 2015; this study’s year is marked. 38 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 192 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 384 across the 95 interventional studies, 833 across the 14 observational. Of the 94 that completed or were terminated, 49 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 109 have an industry lead sponsor. The 10 most frequent:
Shin Poong Pharmaceutical Co. Ltd. is the lead sponsor of 27 studies on the registry; 3 are open to participants now.
Shin Poong Pharmaceutical Co. Ltd. has 5 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
4 of the studies in COVID-19 with a site in South Africa that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928272Phase 3Douglas D. FraserLong Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study | 2026-12 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT04746183University of LiverpoolAGILE (Early Phase Platform Trial for COVID-19) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 109 studies in COVID-19 with a site in South Africa, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This exploratory study is a randomized, single center, open label study of four different experimental treatment arms versus standard of care for the treatment of SARS-CoV-2 infection in symptomatic outpatients with mild disease at the time of enrollment.
This phase 2, exploratory study will be an adaptive, randomized, open label, trial for treatment of individuals in an outpatient settings with mild SARS-CoV-2 infection. The primary outcome is focused on the evaluation of efficacy of the proposed experimental drugs in reducing upper respiratory viral shedding, defined as viral clearance (i.e., negative swab) on Day 7. Key secondary outcomes focus on other measures of viral shedding, safety evaluation, progression to LRTI (defined by resting blood oxygen saturation level [SpO2] \<93% sustained for two readings two hours apart and presence of subjective dyspnoea or cough), disease severity, clinical resolution rate, and cumulative incidence of hospitalization or mortality at Day 28.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Signs of respiratory distress prior to randomization, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 mg oral tablets. Two tablets taken at 6-hour intervals as needed, in all treatment arms (in addition to any investigative treatment)
Drug: Paracetamol
Fixed dose combination tablets containing 100 mg artesunate and 270 mg amodiaquine. Participants received two tablets once daily for 3 days
Drug: Artesunate-amodiaquine
Fixed dose combination tablets containing 180 mg pyronaridine and 60 mg artesunate, given once daily for 3 days. Participants weighing 45 to \<65 kg received 3 tablets per dose, those ≥65 kg received 4 tablets per dose
Drug: Pyronaridine-artesunate
Free combination of favipiravir 200 mg and 400 mg tablets and nitazoxanide 500 mg tablets. Participants received favipiravir as a loading dose of 1600 mg twice daily for 1 day followed by 600 mg twice daily for 6 days, and nitazoxanide 1000 mg twice daily, with food, for 7 days
Drug: Favipiravir plus Nitazoxanide
Fixed dose combination tablets containing 400 mg sofosbuvir and 60 mg daclatasvir. Participants received 1 tablet once daily for 7 days
Drug: Sofosbuvir/daclatasvir
SOC - 2 tablets (1000 mg) to be taken 6-hourly as needed
Also known as: Control treatment (SoC)
Drug pages: Artesunate · Amodiaquine
SOC plus artesunate-amodiaquine (ASAQ) - 2 tablets (200/540 mg artesunate/amodiaquine) daily for 3 days
Also known as: ASAQ
SOC plus pyronaridine-artesunate (PA) Weight 45 to \<65 kg: 3 tablets (540/180 mg pyronaridine/artesunate) daily for 3 days Weight ≥65 kg: 4 tablets (720/240 mg pyronaridine/artesunate) daily for 3 days
Also known as: PA
Drug pages: Favipiravir · Nitazoxanide
SOC plus favipiravir plus nitazoxanide (FPV-NTZ) Favipiravir: 1600 mg 12-hourly for 1 day then 600 mg 12-hourly for 6 days Nitazoxanide: 2 tablets (1000 mg) 12-hourly for 7 days
Also known as: FPV-NTZ
Drug pages: Sofosbuvir · Daclatasvir
SOC plus sofosbuvir/daclatasvir (SOF/DCV) 1 tablet (400 mg/60 mg sofosbuvir/daclatasvir) daily for 7 days
Also known as: SOF/DCV
Incidence of SARS-CoV-2 Clearance
Time frame: Day 7
Incidence of SARS-CoV-2 Clearance
Time frame: Day 3, 10, 14, 21, 28
Time to Clearance of Nasal SARS-CoV-2
Time frame: Day 0, 3, 7, 10, 14, 21, 28
Estimated Viral Load of SARS-CoV-2 Detected by Quantitative RT-PCR
baseline and day14, Day 14 value minus baseline value
Time frame: Day 14
Poisson Regression for Proportion of Days With Fever After Randomization
Time frame: Day 28
Percentage of Days With Respiratory Symptoms After Randomization
"Percentage of total study days in which participants experienced respiratory symptoms until day 28. Percentage calculated as (No. of days with respiratory symptoms) ÷ (No. of days observation) x 100"
Time frame: from randomization to end of study (until day 28)
FLU-PRO Plus Questionnaire Scores and FLU-PRO Plus Global Additional Daily Diary Items Over the First 14 Days
baseline and day 14, Day 14 value minus baseline value The FLU-PRO(inFLUenza Patient-Reported Outcome) Plus questionnaire was completed daily during the first 14 days, at Day 21 and at Day 28. From these items six domain scores for the body areas Nose, Throat, Eyes, Chest/Respiratory, Gastrointestinal, and Body/Systemic could be computed ranging from 0 (symptom free) to 4 (very severe symptoms). Total Score Range for FLU-PRO Plus * Score range per item: 0 (no symptoms) to 4 (very severe symptoms). A higher score indicates worse symptoms. * Total score calculation: The mean (average) of all item scores is used. (Minimum score: 0, Maximum score: 4)
Time frame: 14 days
Serious Adverse Events
Time frame: Day 28
Adverse Events
Time frame: Day 28
Related Adverse Events
Time frame: Day 28
LRTI
Time frame: Day 28
Maximum Score on WHO Ordinal Scale for Clinical Improvement During Study Participation
Time frame: Day 28
Cumulative Incidence of Hospitalization
Time frame: Day 28
Days of Hospitalization
Total number of hospitalization days for hospitalized participants in each group
Time frame: Day 28
Cumulative Incidence of Mortality, Measured at Day 28 or Later if Participant is Hospitalized at the Time of Day 28
Time frame: at Day 28 or later if participant is hospitalized at the time of Day 28 for up to 2 months
| Milestone | Paracetamol (SOC) | SOC Plus Artesunate-Amodiaquine | SOC Plus Favipiravir Plus Nitazoxanide | SOC Plus Pyronaridine-Artesunate | SOC Plus Sofosbuvir/Daclatasvir |
|---|---|---|---|---|---|
| Started | 39 | 39 | 38 | 38 | 38 |
| Completed | 37 | 39 | 36 | 36 | 35 |
| Not completed | 2 | 0 | 2 | 2 | 3 |
| percentage of paticaipants | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Incidence of SARS-CoV-2 Clearance | 34.2 | 38.5 | 30.3 | 27.0 | 23.5 |
| percentage of paticaipants | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Day 3 | 28.2 | 17.9 | 17.1 | 24.3 | 14.3 |
| Day 10 | 33.3 | 33.3 | 40.0 | 29.7 | 34.3 |
| Day 14 | 56.4 | 51.3 | 45.7 | 51.4 | 51.4 |
| Day 21 | 66.7 | 53.8 | 68.6 | 64.9 | 68.6 |
| Day 28 | 71.8 | 66.7 | 68.6 | 73.0 | 68.6 |
| Time(day) | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Time to Clearance of Nasal SARS-CoV-2 | 10 (7 to 14) | 7 (3 to 9) | 8.5 (3 to 14) | 14 (3 to 14) | 8.5 (3 to 14) |
baseline and day14, Day 14 value minus baseline value
| Log₁₀ copies/mL | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Estimated Viral Load of SARS-CoV-2 Detected by Quantitative RT-PCR | -3.81 ± 2.576 | -3.35 ± 2.531 | -3.30 ± 2.283 | -3.50 ± 2.691 | -2.98 ± 2.757 |
| proportion | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Poisson Regression for Proportion of Days With Fever After Randomization | 0.596 | 0.000 | 1.732 | 0.599 | 0.835 |
"Percentage of total study days in which participants experienced respiratory symptoms until day 28. Percentage calculated as (No. of days with respiratory symptoms) ÷ (No. of days observation) x 100"
| Percentage (%) | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Percentage of Days With Respiratory Symptoms After Randomization | 35.66 (28.252 to 38.450) | 28.034 (22.134 to 30.386) | 33.469 (26.451 to 36.416) | 29.602 (23.947 to 32.937) | 35.306 (30.099 to 40.711) |
baseline and day 14, Day 14 value minus baseline value The FLU-PRO(inFLUenza Patient-Reported Outcome) Plus questionnaire was completed daily during the first 14 days, at Day 21 and at Day 28. From these items six domain scores for the body areas Nose, Throat, Eyes, Chest/Respiratory, Gastrointestinal, and Body/Systemic could be computed ranging from 0 (symptom free) to 4 (very severe symptoms). Total Score Range for FLU-PRO Plus * Score range per item: 0 (no symptoms) to 4 (very severe symptoms). A higher score indicates worse symptoms. * Total score calculation: The mean (average) of all item scores is used. (Minimum score: 0, Maximum score: 4)
| score | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| FLU-PRO Plus Questionnaire Scores and FLU-PRO Plus Global Additional Daily Diary Items Over the First 14 Days | -0.750 ± 0.8270 | -0.750 ± 1.0046 | -0.750 ± 0.9079 | -1.250 ± 0.9135 | -0.750 ± 0.5711 |
| Participants | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Serious Adverse Events | 0 | 0 | 0 | 1 | 0 |
| Participants | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Adverse Events | 0 | 0 | 0 | 1 | 1 |
| Participants | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Related Adverse Events | 0 | 11 | 12 | 21 | 10 |
| Participants | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| LRTI | 0 | 0 | 2 | 0 | 1 |
| score | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Maximum Score on WHO Ordinal Scale for Clinical Improvement During Study Participation | 1 ± 0.5 | 0 ± 0.6 | 1 ± 0.76 | 1 ± 0.43 | 1 ± 0.81 |
| Participants | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Cumulative Incidence of Hospitalization | 0 | 0 | 1 | 0 | 1 |
Total number of hospitalization days for hospitalized participants in each group
| Days | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Days of Hospitalization | 0 ± 0 | 0 ± 0 | 6.00 ± 0 | 0 ± 0 | 6.00 ± 0 |
| Participants | Arm A | Arm B | Arm C | Arm D | Arm E |
|---|---|---|---|---|---|
| Cumulative Incidence of Mortality, Measured at Day 28 or Later if Participant is Hospitalized at the Time of Day 28 | 0 | 0 | 0 | 0 | 0 |
Collected over Day 28 and up to 3 months after end of study treatment. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOC (Paracetamol) | 0/39 (0%) | 0/39 (0%) | 14/39 (35.9%) |
| ASAQ | 0/39 (0%) | 0/39 (0%) | 18/39 (46.2%) |
| PA(Pyronaridine-Artesunate) | 0/38 (0%) | 0/38 (0%) | 21/38 (55.3%) |
| FPV-NTZ | 0/36 (0%) | 1/36 (2.8%) | 31/36 (86.1%) |
| SOF/DCV | 0/36 (0%) | 0/36 (0%) | 16/36 (44.4%) |
| Event | SOC (Paracetamol) | ASAQ | PA(Pyronaridine-Artesunate) | FPV-NTZ | SOF/DCV |
|---|---|---|---|---|---|
| PancytopeniaBlood and lymphatic system disorders | 0/39 | 0/39 | 0/38 | 1/36 | 0/36 |
| Event | SOC (Paracetamol) | ASAQ | PA(Pyronaridine-Artesunate) | FPV-NTZ | SOF/DCV |
|---|---|---|---|---|---|
| ChromaturiaRenal and urinary disorders | 0/39 | 0/39 | 1/38 | 11/36 | 0/36 |
| DizzinessNervous system disorders | 4/39 | 2/39 | 9/38 | 4/36 | 3/36 |
| nauseaGastrointestinal disorders | 2/39 | 6/39 | 4/38 | 8/36 | 4/36 |
| Abdominal painGastrointestinal disorders | 2/39 | 2/39 | 4/38 | 8/36 | 2/36 |
| diarrheaGastrointestinal disorders | 5/39 | 3/39 | 3/38 | 7/36 | 4/36 |
| VomitingGastrointestinal disorders | 4/39 | 5/39 | 5/38 | 2/36 | 1/36 |
| HeadacheNervous system disorders | 0/39 | 3/39 | 2/38 | 3/36 | 3/36 |
| Upper respiratory tract infectionInfections and infestations | 0/39 | 0/39 | 3/38 | 0/36 | 1/36 |
| Back painMusculoskeletal and connective tissue disorders | 0/39 | 3/39 | 0/38 | 2/36 | 0/36 |
| InsomniaPsychiatric disorders | 0/39 | 3/39 | 1/38 | 0/36 | 0/36 |
| Age, Categorical(Participants) | Paracetamol (SOC) | ASAQ | PA(Pyronaridine-Artesunate) | FPV-NTZ | SOF/DCV | Total |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 1 | 0 | 0 | 1 |
| Between 18 and 65 years | 39 | 39 | 35 | 37 | 35 | 185 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Paracetamol (SOC) | ASAQ | PA(Pyronaridine-Artesunate) | FPV-NTZ | SOF/DCV | Total |
|---|---|---|---|---|---|---|
| Mean | 33.7 ± 9.93 | 36 ± 10.32 | 35.9 ± 11.28 | 34 ± 9.43 | 34.8 ± 10.58 | 34.9 ± 10.25 |
| Sex: Female, Male(Participants) | Paracetamol (SOC) | ASAQ | PA(Pyronaridine-Artesunate) | FPV-NTZ | SOF/DCV | Total |
|---|---|---|---|---|---|---|
| Female | 24 | 25 | 20 | 15 | 15 | 99 |
| Male | 15 | 14 | 16 | 22 | 20 | 87 |
| Race (NIH/OMB)(Participants) | Paracetamol (SOC) | ASAQ | PA(Pyronaridine-Artesunate) | FPV-NTZ | SOF/DCV | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 3 | 0 | 1 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 36 | 32 | 34 | 32 | 31 | 165 |
| White | 1 | 2 | 2 | 2 | 1 | 8 |
| More than one race | 0 | 2 | 0 | 2 | 2 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Paracetamol (SOC) | ASAQ | PA(Pyronaridine-Artesunate) | FPV-NTZ | SOF/DCV | Total |
|---|---|---|---|---|---|---|
| South Africa — Black African | 36 | 32 | 34 | 32 | 31 | 165 |
| South Africa — Coloured | 0 | 2 | 0 | 2 | 2 | 6 |
| South Africa — White | 1 | 2 | 2 | 2 | 1 | 8 |
| South Africa — Asian or Indian | 2 | 3 | 0 | 1 | 1 | 7 |
| South Africa — Other | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Aug 2021, 11 months.
Results were first posted in Jul 2025, 3 years 11 months after primary completion.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 11 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Artesunate · Amodiaquine · Favipiravir · Nitazoxanide · Sofosbuvir · Daclatasvir
Shin Poong Pharmaceutical Co. Ltd. →